163 related articles for article (PubMed ID: 31629060)
1. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC.
Gascón P; Nagarkar R; Šmakal M; Syrigos KN; Barrios CH; Sánchez JC; Zhang L; Henry DH; Gordon D; Hirsh V; Kubota K; Orlov S; Thomas G; Steinmetz T; Kang JH; Tomita DK; Fleishman AN; Park JK; De Oliveira Brandao C
J Thorac Oncol; 2020 Feb; 15(2):190-202. PubMed ID: 31629060
[TBL] [Abstract][Full Text] [Related]
2. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
Vansteenkiste J; Pirker R; Massuti B; Barata F; Font A; Fiegl M; Siena S; Gateley J; Tomita D; Colowick AB; Musil J;
J Natl Cancer Inst; 2002 Aug; 94(16):1211-20. PubMed ID: 12189224
[TBL] [Abstract][Full Text] [Related]
3. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.
Pirker R; Hedenus M; Vansteenkiste J; Hernandez E; Belton L; Terwey JH
Clin Ther; 2016 Jan; 38(1):122-135.e6. PubMed ID: 26730453
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
[TBL] [Abstract][Full Text] [Related]
6. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
Schwartzberg L; Burkes R; Mirtsching B; Rearden T; Silberstein P; Yee L; Inamoto A; Lillie T
BMC Cancer; 2010 Oct; 10():581. PubMed ID: 20973982
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.
Nangaku M; Kondo K; Ueta K; Kokado Y; Kaneko G; Matsuda H; Kawaguchi Y; Komatsu Y
Nephrol Dial Transplant; 2021 Aug; 36(9):1731-1741. PubMed ID: 33650630
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L
Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia.
Boccia RV; Henry DH; Belton L; Bohac C; Ghazal HH
Cancer Med; 2016 Dec; 5(12):3445-3453. PubMed ID: 27882724
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
[TBL] [Abstract][Full Text] [Related]
12. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
Gordon D; Nichols G; Ben-Jacob A; Tomita D; Lillie T; Miller C
Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
Hernandez E; Ganly P; Charu V; Dibenedetto J; Tomita D; Lillie T; Taylor K;
Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations.
Vansteenkiste J; Poulsen E; Rossi G; Glaspy J
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):45-55. PubMed ID: 12435173
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial.
Liu B; Chen N; Zhao J; Yin A; Wu X; Xing C; Jiang G; Fu J; Wang M; Wang R; Niu J; Fu P; Ni Z; Hou F; Zhao J; Chen J; Chen Y; Shi W; Chen J; Li W; Xu G; Zhong L; Liu W; Ding G; Kondo Y; Yue C; Mei C
Chronic Dis Transl Med; 2022 Jun; 8(2):134-144. PubMed ID: 35774427
[TBL] [Abstract][Full Text] [Related]
16. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
[TBL] [Abstract][Full Text] [Related]
17. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
Auerbach M; Silberstein PT; Webb RT; Averyanova S; Ciuleanu TE; Shao J; Bridges K
Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
[TBL] [Abstract][Full Text] [Related]
18. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.
Pirker R; Ramlau RA; Schuette W; Zatloukal P; Ferreira I; Lillie T; Vansteenkiste JF
J Clin Oncol; 2008 May; 26(14):2342-9. PubMed ID: 18467726
[TBL] [Abstract][Full Text] [Related]
20. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials.
Hedenus M; Vansteenkiste J; Kotasek D; Austin M; Amado RG
J Clin Oncol; 2005 Oct; 23(28):6941-8. PubMed ID: 16192582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
